Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience.
Adult
Behcet Syndrome
/ complications
Cataract
/ complications
Female
Fluorescein Angiography
HLA-B51 Antigen
/ biosynthesis
Humans
Italy
Macular Edema
/ drug therapy
Male
Middle Aged
Ophthalmology
Panuveitis
/ complications
Prognosis
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Uveitis
/ complications
Young Adult
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
02
2020
revised:
08
04
2020
accepted:
28
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
10
7
2021
Statut:
epublish
Résumé
To examine demographic and clinical characteristics and long-term visual outcome in a cohort of Italian patients affected by Behçet's uveitis (BU). Retrospective chart review of 47 patients with BU attending our unit between January 2018 and December 2019. Ophthalmologic manifestations, best-corrected visual acuity (BCVA), fluoroangiography and optical coherence tomography findings, and ocular complications were recorded. Predictive factors of a poor visual outcome and long-term complications were also investigated. Forty-seven patients (23 males and 24 females) for a total of 84 eyes were enrolled. Uveitis was bilateral in 37 (78.7%) patients with panuveitis being the most frequent anatomical pattern (40 out of 84 eyes), whereas 27 eyes presented a posterior uveitis. Isolated anterior uveitis was detected in 16 eyes. A significant improvement of median BCVA between baseline and last follow-up values was detected ( In Italian patients, BU typically arises in the third decade and predominantly manifests as a bilateral posterior uveitis or panuveitis. Its duration is associated with a poor visual prognosis. Uveitis duration, the presence of HLA-B51, and panuveitis are predictors of long-term structural complications, thus representing main drivers in the treatment decision-making.
Identifiants
pubmed: 32508524
doi: 10.1155/2020/6872402
pmc: PMC7245671
doi:
Substances chimiques
HLA-B51 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6872402Informations de copyright
Copyright © 2020 Jurgen Sota et al.
Déclaration de conflit d'intérêts
The authors declare that the research was carried out in the absence of any personal, professional, or financial relationships that could potentially be construed as a conflict of interest.
Références
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Br J Ophthalmol. 2018 May;102(5):637-641
pubmed: 28844047
Ophthalmology. 1995 Feb;102(2):317-21
pubmed: 7862420
Medicine (Baltimore). 2003 Jan;82(1):60-76
pubmed: 12544711
Ocul Immunol Inflamm. 2020;28(2):298-304
pubmed: 30148652
Isr Med Assoc J. 2017 Aug;19(8):478-483
pubmed: 28825765
Arthritis Rheum. 2010 Sep;62(9):2806-12
pubmed: 20496419
Semin Ophthalmol. 2017;32(6):764-771
pubmed: 27715380
Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):68-73
pubmed: 30582503
J Fr Ophtalmol. 2019 Apr;42(4):e133-e146
pubmed: 30850197
Intern Emerg Med. 2020 Feb 1;:
pubmed: 32006221
Clin Rheumatol. 2018 Jun;37(6):1715-1720
pubmed: 29671190
Eur J Ophthalmol. 2008 Jul-Aug;18(4):563-6
pubmed: 18609475
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47
pubmed: 23441863
Ann Rheum Dis. 2018 Jun;77(6):808-818
pubmed: 29625968
Ocul Immunol Inflamm. 2017 Feb;25(1):29-36
pubmed: 26727030
Acta Ophthalmol (Copenh). 1992 Dec;70(6):786-9
pubmed: 1488888
Ocul Immunol Inflamm. 2019;27(1):2-6
pubmed: 29020486
Adv Exp Med Biol. 2003;528:123-6
pubmed: 12918675
Intern Emerg Med. 2017 Oct;12(7):947-955
pubmed: 28620840
Clin Rheumatol. 2018 Oct;37(10):2805-2809
pubmed: 29766375
Rev Med Interne. 2005 Oct;26(10):771-6
pubmed: 16169129
Ocul Immunol Inflamm. 2002 Mar;10(1):53-63
pubmed: 12461704
Ocul Immunol Inflamm. 2019;27(1):34-39
pubmed: 29099660
Am J Ophthalmol. 2004 Sep;138(3):373-80
pubmed: 15364218
Yonsei Med J. 1997 Dec;38(6):411-22
pubmed: 9509911
Br J Ophthalmol. 2007 Dec;91(12):1579-82
pubmed: 18024808
Clin Rev Allergy Immunol. 2015 Dec;49(3):298-306
pubmed: 24828904
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Ocul Immunol Inflamm. 2015;23 Suppl 1:S1-23
pubmed: 26167846
Eye (Lond). 2009 May;23(5):1182-6
pubmed: 18551141
Curr Rheumatol Rev. 2019 Oct 06;:
pubmed: 31804160
Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):661-6
pubmed: 18982344